Abstract 42P
Background
The study investigates the potential of OZ-001, a novel 3,4-dihydroquinazoline derivative containing a ureido group, against diverse cancers. Conventional chemotherapy has limited impact on triple-negative breast cancer (TNBC), and targeted TNBC therapies are lacking. OZ-001 is expected to target both signal transducer and activator of transcription 3 (STAT3) inhibition and T-type calcium channel blocking simultaneously.
Methods
The efficacy and potency of OZ-001 were assessed using MDA-MB-231 cells both in vitro and in vivo. Cell-based assays compassing cell viability, apoptosis, protein expression, cell cycle analysis, fluorescence polarization assay (FP), and intracellular calcium levels were conducted. An in vivo xenograft model using MB-231 cells gauged impact of OZ-001 via oral administration (ranging from 15 to 60mg/kg). Preliminary toxicity evaluation of OZ-001 was conducted using an in vivo model with RD rats.
Results
In vitro, OZ-001 displayed substantial does-dependent inhibition of cell viability inducing a remarkable 10-fold increase in apoptotic genes Bax and caspase-3 compared to the control. As a STAT3 inhibitor, OZ-001 effectively disrupted STAT3-STAT3 interactions in the FP assay, and it reduce STAT3 phosphorylation by 90%. As a T-type calcium channel blocker, OZ-001 exhibited the capability to reduce intracellular calcium levels by 50%, resulting in a notable 90% reduction in calcium signaling. In vivo, OZ-001 led to a 50% reduction in tumor size at a dose of 15mg/kg, and an impressive 95% at 60mg/kg (P.O.), compared to the vehicle-treated group, while a 70% reduction in tumor size at a dose of 10 mg/kg (IP) of Paclitaxel was observed. In a single oral dose toxicity evaluation using SD rats, no specific clinical sign or distinctive necropsy findings were observed, even at a dose of 2,000 mg/kg of OZ-001. This indicates its favorable safety profile.
Conclusions
OZ-001 emerges as a promising therapeutic candidate for TNBC, demonstrating exceptional efficacy as an orally active single agent in reducing tumor growth. The preclinical results present an encouraging avenue for further exploration and development of OZ-001 as a viable alternative for addressing TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ONCOZEN Co., Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract